Skip to main content

Teva Pharmaceutical Value Stock - Dividend - Research Selection

Teva pharmaceutical

ISIN: US8816242098 , WKN: 883035

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment\'s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Teva Pharmaceutical Industries Subsidiary And Medincell Says European Medicines Agency Has Accepted The Marketing Authorization Application For Olanzapine Long-Acting Injectable (TEV-'749) For The Treatment Of Schizophrenia In Adults

2026-05-21
The olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a significant unmet

Teva Pharmaceutical Industries Announces New Data Highlighting Significant Gap In Diagnosing Tardive Dyskinesia In Teen Patients With Underlying Mood Disorders

2026-05-18
The IMPACT-TD findings revealed:A majority of participants, regardless of age, reported a moderate to severe global impact from TD. This burden was particularly high for those aged 18-29 (85%) and 50-59 (87%, n=57),

Novo Nordisk: Why A P/E Of 13 Is A Value Trap, Not A Bargain

2026-05-13
Novo Nordisk (NVO) faces semaglutide patent cliffs and looming generics—could profits drop 40%? Get valuation and HOLD insights now—read before you buy.

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

2026-05-12
Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference 2026 May 12, 2026 12:20 PM EDTCompany ParticipantsEric Hughes -...

Teva's CNS Portfolio Is Growing, But Valuation Is Stretched

2026-05-11
Teva trades at the non-GAAP P/E ratio of 14.93x, which is 65.9% higher than Sanofi's. Find out why TEVA stock is a Sell.

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

2026-05-06
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $38 to $40.

10 Health Care Stocks With Whale Alerts In Today's Session

2026-05-01

JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

2026-04-30
JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $35 to $40.

UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

2026-04-30
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $36 to $42.

Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

2026-04-30
Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $41 to $42.